Polyhexamethylene biguanide (PHMB) 0.08% has received the orphan drug designation for management of Acanthamoeba keratitis (AK). This review aimed to evaluate the clinical efficacy and safety of PHMB, comparing outcomes across different concentrations (0.08% vs. 0.02%) using a dose-stratified meta-analysis.
Methods
Online databases were searched until February 2025 for studies on PHMB 0.02% or 0.08% as mono- or combination therapy. The primary outcome was clinical cure and secondary outcomes included conjunctival hyperemia and pain. Subgroup analyses were performed based on PHMB concentration. A random-effects model was applied; sensitivity analyses and publication bias assessments were conducted.
Results
The pooled proportion of cure across 17 studies (923 eyes) was 75.75% (95% CI: 64.56%–84.27%; p < 0.0001; I² = 85.2%). Subgroup analysis showed the highest cure rate with PHMB 0.08% monotherapy (87.04%; 95% CI: 77.54%–92.88%), followed by 0.02% monotherapy (79.27%; 95% CI: 65.29%–88.60%) and mixed 0.02% regimens (72.59%; 95% CI: 54.86%–85.23%). Conjunctival hyperemia was reported in 15.7%, and subgroup analysis by dose revealed highest prevalence in the 0.08% PHMB group (26.4%; 95% CI: 8.4%–49.2%). Pain was reported in 11.9% (n = 225), with no significant increase at higher concentrations. The pooled proportion of overall adverse events was 40.2% (95% CI 26.2%–55.0%; p < 0.0001; I² = 81.4%). Findings were robust across sensitivity analyses, with no publication bias detected.
Conclusion
This dose-stratified meta-analysis found PHMB 0.08% monotherapy to have good efficacy and tolerability, supporting its use as a first-line empirical treatment and underscoring the need for standardized protocols and comparative trials.
JonesDBVisvesvaraGSRobinsonNM. Acanthamoeba polyphaga keratitis and Acenthamoeba uveitis associated with fatal meningoencephalitis. Trans Ophthalmol Soc U K (1962)1975; 95: 221–232.
2.
JonesBRMcGillJISteeleAD. Recurrent suppurative kerato-uveitis with loss of eye due to infection by Acanthamoeba castellani. Trans Ophthalmol Soc U K (1962)1975; 95: 210–213.
3.
DaasLSzentmáryNEppigT, et al.Das Deutsche Akanthamöbenkeratitis-Register: erste Ergebnisse einer multizentrischen Erhebung. Ophthalmologe2015; 112: 752–763. DOI: 10.1007/s00347-014-3225-7.
4.
SzentmáryNDaasLShiL, et al.Acanthamoeba keratitis - clinical signs, differential diagnosis and treatment. J Curr Ophthalmol2019; 31: 16–23. DOI: 10.1016/j.joco.2018.09.008.
PetrilloFTortoriAVallinoV, et al.Understanding Acanthamoeba keratitis: an in-depth review of a sight-threatening eye infection. Microorganisms2024; 12: 758. DOI: 10.3390/microorganisms12040758.
7.
PatelNVMathurUSawantS,et al.Three consecutive cases of ocular polyhexamethylene biguanide (PHMB) toxicity due to compounding error. CureusPublished online May 4, 2023. DOI: 10.7759/cureus.38540.
SterneJACSavovićJPageMJ, et al.Rob 2: a revised tool for assessing risk of bias in randomised trials. Br Med JPublished online August 28, 2019: l4898. DOI: 10.1136/bmj.l4898.
12.
SterneJAHernánMAReevesBC, et al.ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Br Med J2016; 355: i4919. DOI: 10.1136/bmj.i4919.
PrasadM. Introduction to the GRADE tool for rating certainty in evidence and recommendations. Clin Epidemiol Glob Health2024; 25: 101484. DOI: 10.1016/j.cegh.2023.101484.
DartJKGPapaVRamaP, et al.The orphan drug for Acanthamoeba keratitis (ODAK) trial. Ophthalmology2024; 131: 277–287. DOI: 10.1016/j.ophtha.2023.09.031.
17.
FranchAKnutssonKAPedrottiE, et al.Treatment of Acanthamoeba keratitis with high dose PHMB (0.08%) monotherapy in clinical practice: a case series. Eur J OphthalmolPublished online November 14, 2025; 35: 1235–1241. DOI: 10.1177/11206721241299470.
18.
Di ZazzoADe GregorioCCoassinM. Novel effective medical therapy for Acanthamoeba keratitis. Eye Contact LensPublished online May 1, 2024; 50: 279–281. DOI: 10.1097/ICL.0000000000001092.
19.
PapaVVan Der MeulenIRotteyS, et al.Safety and tolerability of topical polyhexamethylene biguanide: a randomised clinical trial in healthy adult volunteers. Br J Ophthalmol2022; 106: 190–196. DOI: 10.1136/bjophthalmol-2020-317848.
20.
LimNGohDBunceC, et al.Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. Am J Ophthalmol2008; 145: 130–135. DOI: 10.1016/j.ajo.2007.08.040.
21.
BaggaBSharmaSGourRPS, et al.A randomized masked pilot clinical trial to compare the efficacy of topical 1% voriconazole ophthalmic solution as monotherapy with combination therapy of topical 0.02% polyhexamethylene biguanide and 0.02% chlorhexidine in the treatment of Acanthamoeba keratitis. Eye2021; 35: 1326–1333. DOI: 10.1038/s41433-020-1109-4.
22.
PapaVRamaPRadfordC, et al.Acanthamoeba keratitis therapy: time to cure and visual outcome analysis for different antiamoebic therapies in 227 cases. Br J Ophthalmol2020; 104: 575–581. DOI: 10.1136/bjophthalmol-2019-314485.
23.
RandagACVan RooijJVan GoorAT, et al.The rising incidence of Acanthamoeba keratitis: a 7-year nationwide survey and clinical assessment of risk factors and functional outcomes. Oldenburg CE, ed. PLoS One2019; 14: e0222092. DOI: 10.1371/journal.pone.0222092.
24.
MusayevaARiedlJCSchusterAK, et al.Topical voriconazole as supplemental treatment for Acanthamoeba keratitis. Cornea2020; 39: 986–990. DOI: 10.1097/ICO.0000000000002315.
25.
DuguidIGMDartJKGMorletN, et al.Outcome of Acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine. Ophthalmology1997; 104: 1587–1592. DOI: 10.1016/S0161-6420(97)30092-X.
26.
MeghaKThakurAKhuranaS, et al.Acanthamoeba keratitis: a 4-year review from a tertiary care hospital in North India. Nep J Oph2020; 12: 83–90. DOI: 10.3126/nepjoph.v12i1.24769.
27.
Azuara-BlancoASadiqASHussainM, et al.Successful medical treatment of Acanthamoeba keratitis. Int Ophthalmol1997; 21: 223–227. DOI: 10.1023/A:1006055918101.
ChinJYoungALHuiM,et al.Acanthamoeba keratitis: 10-year study at a tertiary eye care center in Hong Kong. Cont Lens Anterior Eye2015; 38: 99–103. DOI: 10.1016/j.clae.2014.11.146.
30.
VargaJHWolfTCJensenHG, et al.Combined treatment of Acanthamoeba keratitis with propamidine, neomycin, and polyhexamethylene biguanide. Am J Ophthalmol1993; 115: 466–470. DOI: 10.1016/S0002-9394(14)74448-4.
31.
RadfordCFLehmannOJDartJKG. Acanthamoeba keratitis: multicentre survey in England 1992-6. Br J Ophthalmol1998; 82: 1387–1392. DOI: 10.1136/bjo.82.12.1387.
32.
DonosoRMuraJJLópezM. Acanthamoeba keratitis treated with propamidine and polyhexamethyl biguanide (PHMB). Rev Med Chil2002; 130: 396–401.
33.
Dos SantosDLKwitkoSMarinhoDR, et al.Acanthamoeba keratitis in Porto Alegre (southern Brazil): 28 cases and risk factors. Parasitol Res2018; 117: 747–750. DOI: 10.1007/s00436-017-5745-y.
34.
LarkinDFPKilvingtonSDartJKG. Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology1992; 99: 185–191. DOI: 10.1016/S0161-6420(92)31994-3.
35.
MurdochDGrayTBCursonsR,et al.Acanthamoeba keratitis in New Zealand, including two cases with in vivo resistance to polyhexamethylene biguanide. Aust N Z J Ophthalmol1998; 26: 231–236. DOI: 10.1111/j.1442-9071.1998.tb01317.x.
ChewHFYildizEHHammersmithKM, et al.Clinical outcomes and prognostic factors associated with Acanthamoeba keratitis. Cornea2011; 30: 435–441. DOI: 10.1097/ICO.0b013e3181ec905f.
38.
DartJKGSawVPJKilvingtonS. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol2009; 148: 487–499.e2. DOI: 10.1016/j.ajo.2009.06.009.
39.
RaghavanARammohanR. Acanthamoeba keratitis - a review. Indian J Ophthalmol2024; 72: 473–482. DOI: 10.4103/IJO.IJO_2627_23.
40.
AlkharashiMLindsleyKLawHA, et al.Medical interventions for Acanthamoeba keratitis. Cochrane Eyes and Vision Group, ed. Cochrane Database Syst Rev2015; 2015. DOI: 10.1002/14651858.CD010792.pub2.
41.
BaconASFrazerDGDartJKG, et al.A review of 72 consecutive cases of Acanthamoeba keratitis, 1984–1992. Eye1993; 7: 719–725. DOI: 10.1038/eye.1993.168.
42.
RobaeiDCarntNMinassianDC,et al.Therapeutic and optical keratoplasty in the management of Acanthamoeba keratitis. Ophthalmology2015; 122: 17–24. DOI: 10.1016/j.ophtha.2014.07.052.
43.
ManikandanPBhaskarMRevathyR, et al.Acanthamoeba keratitis - a six year epidemiological review from a tertiary care eye hospital in South India. Indian J Med Microbiol2004; 22: 226–230. DOI: 10.1016/S0255-0857(21)02767-5.
44.
LalithaPLinCCSrinivasanM, et al.Acanthamoeba keratitis in South India: a longitudinal analysis of epidemics. Ophthalmic Epidemiol2012; 19: 111–115. DOI: 10.3109/09286586.2011.645990.
45.
LeeJEOumBSChoiHY, et al.Cysticidal effect on Acanthamoeba and toxicity on human keratocytes by polyhexamethylene biguanide and chlorhexidine. Cornea2007; 26: 736–741. DOI: 10.1097/ICO.0b013e31805b7e8e.
46.
ShiLStachonTSeitzB, et al.The effect of antiamoebic agents on viability, proliferation and migration of human epithelial cells, keratocytes and endothelial cells, In Vitro. Curr Eye Res2018; 43: 725–733. DOI: 10.1080/02713683.2018.1447674.
47.
BücheleMLCNunesBFFilippin-MonteiroFB,et al.Diagnosis and treatment of Acanthamoeba keratitis: a scoping review demonstrating unfavorable outcomes. Cont Lens Anterior Eye2023; 46: 101844. DOI: 10.1016/j.clae.2023.101844.
48.
PapaVvan Der MeulenIJERotteyS, et al.Ocular safety of high doses polyhexanide (PHMB) in healthy volunteers. Invest Ophthalmol Visual Sci2017; 58: 5170–5170.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
